Voice from the field: Roberto Arroba

Коста-Рика
10 апре́ль 2017

Roberto Arroba is the National coordinator of immunization in Costa Rica, in charge of the secretariat of the NITAG and also a core group member of the Global NITAG Network (GNN).

AMP_HD_20160511-194-2.jpg

You attended the GNN meeting last year, what was the main take home message?
NITAGs should be a priority for countries. They are the ones driving national immunization policies. Not only should NITAG meetings be held on a regular basis but also tackle national priority topics.


You are part of the GNN core group, what is the priority for the network?
The core group needs to be established officially in order to meet, if not in person, at least virtually. 


What’s happening for the NITAG in Costa Rica at the moment?
We are currently finishing a cost-effectiveness study on HPV. Hopefully, it will be over by May 2017. If it is cost-effective, it will lead to the NITAG recommendation to introduce the vaccine in the country. Similarly, the rotavirus vaccine was recommended by the NITAG following a cost-effectiveness study and we are now waiting to get the funding to introduce it. We are also very busy with the implementation of a national computerized nominal immunization registry that was recommended by the NITAG 4 years ago. The Ministry of Health is now enforcing the advice. The nominal immunization registry will be piloted in the private sector first.

 

Другие новости по теме & События

  • Коста-Рика

    Costa Rica introduces two new vaccines into the national immunization program

    16.10.2017

    October 2017 marks the introduction of the rotavirus and human papillomavirus (HPV) vaccines in Costa Rica’s immunization program. This decision results from the recommendations of the country National Immunization Technical Advisory Group (NITAG). Since 2001, Costa Rica’s NITAG, which is called Comisión Nacional de Vacunación y Epidemiología (National Commission on Vaccination and Epidemiology), is in charge of establishing and periodically updating the national immunization schedule as well as formulating overall policies and strategies for immunization. In order to issue the recommendations, the NITAG conducted cost-effectiveness studies that were then approved by its members.

    Читать далее
  • Коста-Рика

    Повестка дня регионального семинара ProVac

    17.03.2016

    Семинар посвящен использованию инструментов и методов оценки воздействия, затрат и экономической эффективности вакцин с целью содействия в разработке обоснованной политики иммунизации. На семинаре будут представлены наглядные примеры по вакцинации против менингококковой инфекции.

    Ожидаемые результаты:

    1. Участники смогут способствовать процессу принятия решений на основе фактических данных для разработки национальной политики иммунизации.
    2. Участники углубят свои знания в области использования экономических оценок для информирования и принятия решений на основе фактических данных.
    3. Участники будут способны применять усвоенные методы для анализа соотношения затраты-эффективность на национальном уровне при технической поддержке со стороны Инициативы ProVac ПАОЗ.
    4. Участники будут вооружены новыми инструментами и подходами для определения национальных приоритетов в области разработки политики иммунизации.
    Читать далее
  • SAGE (Стратегическая консультативная группа экспертов)

    new Interim Recommendations on Vaccination against Ebola Virus Disease from SAGE

    13.05.2019

    Over the last four weeks, the Ebola outbreak in the Eastern Provinces of the Democratic Republic of Congo (DRC) has deteriorated with a large increase in the number of cases1. A major factor in this rise is an increase in critical security incidents that have dramatically affected the ability to identify, follow up and vaccinate contacts successfully. This context challenges the implementation of ring vaccination based on the identification of contacts and contacts of contacts, as recommended by SAGE in April 2017 and confirmed by SAGE during its April 2019 meeting. Further, a potential vaccine shortage may manifest in case the outbreak expands further and/or is prolonged.

    Читать далее